NextCure, Inc. (NXTC): Price and Financial Metrics
GET POWR RATINGS... FREE!
NXTC POWR Grades
- NXTC scores best on the Value dimension, with a Value rank ahead of 76.32% of US stocks.
- The strongest trend for NXTC is in Stability, which has been heading up over the past 199 days.
- NXTC's current lowest rank is in the Growth metric (where it is better than 4.37% of US stocks).
NXTC Stock Summary
- NXTC's went public 2 years ago, making it older than just 3.67% of listed US stocks we're tracking.
- NXTC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 7.66% of US stocks.
- As for revenue growth, note that NXTC's revenue has grown 252.58% over the past 12 months; that beats the revenue growth of 97.47% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to NextCure Inc, a group of peers worth examining would be DCPH, QURE, ANAB, RCUS, and SURF.
- Visit NXTC's SEC page to see the company's official filings. To visit the company's web site, go to www.nextcure.com.
NXTC Price Target
For more insight on analysts targets of NXTC, see our NXTC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.38 | Average Broker Recommendation | 1.72 (Moderate Buy) |
NXTC Stock Price Chart Interactive Chart >
NXTC Price/Volume Stats
| Current price | $8.14 | 52-week high | $37.47 |
| Prev. close | $8.01 | 52-week low | $7.42 |
| Day low | $7.88 | Volume | 148,400 |
| Day high | $8.26 | Avg. volume | 241,377 |
| 50-day MA | $9.93 | Dividend yield | N/A |
| 200-day MA | $10.52 | Market Cap | 224.75M |
NextCure, Inc. (NXTC) Company Bio
NextCure, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
Latest NXTC News From Around the Web
Below are the latest news stories about NextCure Inc that investors may wish to consider to help them evaluate NXTC as an investment opportunity.
NextCure Reports First Quarter 2021 Financial ResultsBELTSVILLE, Md., May 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2021 financial results and provided a business update. “We are highly focused on advancing our three clinical programs and broadening our pipeline of novel immunomedicines this year. We are committed to continuing to evaluate NC318 in multiple indications in our Phase 2 monotherapy trial as well as the Phase 2 investigator-initiated clinical trial at Yale University that recently commenced,” said Michael Richman, NextCure’s president and chief executive officer. “The NC410 program continues to advance and we w... |
NextCure (NXTC) Presents At 20th Annual Needham Healthcare Conference - SlideshowThe following slide deck was published by NextCure, Inc. in conjunction with this event.... |
NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinical and investigational new drug (IND)-enabling data for NC762 at the American Association for Cancer Research (AACR) Annual Meeting 2021. NC762 is a humanized monoclonal antibody specific for B7-H4 and is being developed for the treatment of cancer. “The research presented by our team reinforces our confidence that NC762, our third program, is a novel immunomedicine with unique anti-tumor properties. We believe it has the potential to provide benefit in multiple oncology indications, particularly in cancers wher... |
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsBELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update. “Our team has worked diligently throughout 2020 to advance our programs despite the difficult environment created by the COVID-19 pandemic. We are thrilled that Dr. Han Myint has recently joined NextCure as our Chief Medical Officer and we are poised to harness his expertise in oncology product development to further advance our product pipeline. As we enter 2021, we are excited to announce the expansion of our pipeline. We remain encourag... |
REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4. The event will be available via conference call and webcast. To listen to the call, please dial: US/CANADA Toll-Free Dial-In Number: (877) 665-6632International Dial-In Number: (602) 563-8471Conference ID: 6773907 A live webcast of the event will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available approximately two hours after the event and archived on the websi... |
NXTC Price Returns
| 1-mo | -14.04% |
| 3-mo | -39.16% |
| 6-mo | -19.49% |
| 1-year | -77.06% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -25.32% |
| 2020 | -80.65% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...